{"pub": "marketwatch", "url": "https://marketwatch.com/story/johnson-johnson-commits-500-million-over-four-years-to-help-end-hiv-tb-epidemics-2019-10-04", "downloaded_at": "2019-10-04 12:34:08.898422+00:00", "title": "Johnson & Johnson commits $500 million over four years to help end HIV, TB epidemics", "language": "en", "text": "Johnson & Johnson JNJ, -0.61% said Friday it is committing $500 million over four years to help end the epidemics of HIV and Tuberculosis. The New Brunswick, N.J.-based drug company said it will dedicate a team of researchers to leverage its scientific resources to accelerate the discovery of next-generation medicines and vaccines to complement current investments by governments. The company's Janssen Pharmaceutical Cos. unit has eight HIV medicines on the market. About 37 million people are currently infected with HIV and about two million are newly infected every year, it said. Janssen will work to develop an investigational mosaic-based vaccine regimen to prevent HIV with a group of partners. The company will also work to help fully eliminate TB as part of a United Nations initiative that aims to eradicate TB by 2030. Shares were slightly higher premarket, but have gained just 1.7% in 2019, while the Dow Jones Industrial Average DJIA, +0.47% has gained 12% and the S&P 500 SPX, +0.80% has gained 16%.", "description": "Johnson & Johnson said Friday it is committing $500 million over four years to help end the epidemics of HIV and Tuberculosis. The New Brunswick,...", "authors": ["Ciara Linnane", "Corporate News Editor"], "top_image": "https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png", "published_at": "2019-10-04"}